Thus, the use of BTK inhibitors as a therapeutic option might reduce ALDH-positive CSC and, at the same time, enhance the radio- as well chemo-sensitivity of HNSCC [30]. The gene discussed is BTK; the disease is head and neck squamous cell carcinoma.